Defence And Security Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for the Active Substance Dydrogesterone Estradiol (Excluding Sequential Preparations), Atc G03fb08 for the Period May 1St, 2023 - April 30Th, 2025

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Tofacitinib (L04aa29) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Aripiprazole, as a Depot Injection Suspension (N05ax12) - (Open House Model)

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Formoterol and Aclidinium Bromide (R03al05) as Part of an Open House Model.

Open House Biologics Rebate Contracts 2023-02 - Follitropin Beta

Open House Discount Contracts 2023-04

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Urapidil (C02ca06) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Baricitinib (L04aa37) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Tamsulosin/Dutasteride (Atc Code Who: G04ca52)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Secukinumab (L04ac10) as Part of a So-Called Open House Model.